Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Capital Expenditures (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Capital Expenditures for 14 consecutive years, with $208000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Capital Expenditures changed N/A year-over-year to $208000.0, compared with a TTM value of $317000.0 through Dec 2025, down 84.99%, and an annual FY2025 reading of $317000.0, down 81.42% over the prior year.
  • Capital Expenditures was $208000.0 for Q2 2025 at Heron Therapeutics, up from $109000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.5 million in Q3 2021 and bottomed at $45000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $486125.0, with a median of $356000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures plummeted 97.06% in 2022, then surged 1662.22% in 2023.
  • Year by year, Capital Expenditures stood at $390000.0 in 2021, then increased by 6.15% to $414000.0 in 2022, then plummeted by 39.61% to $250000.0 in 2023, then surged by 155.2% to $638000.0 in 2024, then plummeted by 67.4% to $208000.0 in 2025.
  • Business Quant data shows Capital Expenditures for HRTX at $208000.0 in Q2 2025, $109000.0 in Q1 2025, and $638000.0 in Q4 2024.